|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-3-27
|
|
pubmed:abstractText |
We describe the case of a 52-year-old Japanese woman with advanced adenocarcinoma of the lung, in whom once-daily treatment with 250 mg ZD1839 ('Iressa') demonstrated a marked antitumour effect. She had initially achieved a partial response with cisplatin-based combination chemotherapy, but had subsequently progressed and had failed to respond to salvage chemotherapy. She had also received whole-brain irradiation for brain metastases. On admission, the patient was confined to bed due to dyspnoea and had rapidly progressing hypoxia secondary to lymphangitis carcinomatosa and a massive right pleural effusion. She was treated with oxygen supplementation and oral ZD1839, which, within a week, led to marked tumour regression and gradually improving dyspnoea. The main adverse event observed was a grade 2 rash. A month after starting ZD1839 treatment, the patient was discharged without the need for oxygen supplementation and had since returned to full-time work. This is a demonstration of ZD1839 producing a dramatic clinical response when administered to a patient with poor performance status who had received extensive prior treatment with cytotoxic agents.'Iressa' is a trademark of the AstraZeneca group of companies.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Paclitaxel,
http://linkedlifedata.com/resource/pubmed/chemical/Protein-Tyrosine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Quinazolines,
http://linkedlifedata.com/resource/pubmed/chemical/Taxoids,
http://linkedlifedata.com/resource/pubmed/chemical/docetaxel,
http://linkedlifedata.com/resource/pubmed/chemical/gefitinib,
http://linkedlifedata.com/resource/pubmed/chemical/irinotecan
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0169-5002
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
40
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
73-6
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:12660009-Adenocarcinoma,
pubmed-meshheading:12660009-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:12660009-Camptothecin,
pubmed-meshheading:12660009-Carcinoma, Non-Small-Cell Lung,
pubmed-meshheading:12660009-Cisplatin,
pubmed-meshheading:12660009-Enzyme Inhibitors,
pubmed-meshheading:12660009-Epidermal Growth Factor,
pubmed-meshheading:12660009-Female,
pubmed-meshheading:12660009-Humans,
pubmed-meshheading:12660009-Lung Neoplasms,
pubmed-meshheading:12660009-Middle Aged,
pubmed-meshheading:12660009-Neoplasm Staging,
pubmed-meshheading:12660009-Paclitaxel,
pubmed-meshheading:12660009-Protein-Tyrosine Kinases,
pubmed-meshheading:12660009-Quinazolines,
pubmed-meshheading:12660009-Salvage Therapy,
pubmed-meshheading:12660009-Taxoids,
pubmed-meshheading:12660009-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
|
|
pubmed:affiliation |
Department of Internal Medicine II, Okayama University Medical School, 2-5-1 Shikatacho, Okayama, 700-8558, Japan. keiich@md.okayama-u.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Case Reports
|
